DBV Technologies (DBVT) Competitors

Oculis (NASDAQ:OCS) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Does the media prefer OCS or DBVT?

In the previous week, Oculis had 5 more articles in the media than DBV Technologies. MarketBeat recorded 9 mentions for Oculis and 4 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.76 beat Oculis' score of -0.09 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DBV Technologies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate OCS or DBVT?

Oculis presently has a consensus price target of $35.33, indicating a potential upside of 80.00%. DBV Technologies has a consensus price target of $14.75, indicating a potential upside of 69.15%. Given Oculis' stronger consensus rating and higher possible upside, research analysts clearly believe Oculis is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
DBV Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Is OCS or DBVT more profitable?

DBV Technologies has a net margin of -815.73% compared to Oculis' net margin of -8,043.28%. Oculis' return on equity of -71.31% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,043.28%	-71.31%	-56.85%
DBV Technologies	-815.73%	-106.07%	-76.17%

Which has more risk and volatility, OCS or DBVT?

Oculis has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -0.63, suggesting that its stock price is 163% less volatile than the S&P 500.

Do insiders and institutionals hold more shares of OCS or DBVT?

22.3% of Oculis shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 1.4% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has preferable earnings and valuation, OCS or DBVT?

DBV Technologies has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$980K	874.58	-$98.92M	-$2.64	-7.44
DBV Technologies	$15.73M	15.18	-$72.73M	-$4.92	-1.77

Does the MarketBeat Community believe in OCS or DBVT?

DBV Technologies received 375 more outperform votes than Oculis when rated by MarketBeat users. However, 91.89% of users gave Oculis an outperform vote while only 54.17% of users gave DBV Technologies an outperform vote.

Company	Underperform	Outperform
Oculis	Outperform Votes 34 91.89%	Underperform Votes 3 8.11%
DBV Technologies	Outperform Votes 409 54.17%	Underperform Votes 346 45.83%

Summary

Oculis beats DBV Technologies on 9 of the 17 factors compared between the two stocks.